Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss		$ (60,557)	$ (7,014)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		899	392
Stock-based compensation		43,390	3,329
Change in fair value of liabilities		(5,282)	(50)
Warrant expense in connection with Merger		154	0
Amortization of debt issuance costs		144	167
Non-cash other		959	(19)
Changes in operating assets and liabilities:
Inventory		(3,047)	(2,004)
Prepaid expenses and other current assets		(4,635)	(950)
Other long-term assets		(58)	733
Accounts payable		7,353	(1,061)
Accrued liabilities		5,583	741
Deferred revenue		(253)	264
Other long-term liabilities		3	126
Net cash used in operating activities		(15,347)	(5,346)
Investing activities
Purchases of investments		(187,521)	(48,908)
Maturities of investments		48,421	34,090
Proceeds from sales of investments		1,215	9,800
Investment in website development and internal-use software		(1,833)	(1,050)
Purchases of property, equipment, and intangible assets		(122)	(801)
Acquisition of business, net of cash acquired		(748)	0
Net cash used in investing activities		(140,588)	(6,869)
Financing activities
Proceeds from issuance of redeemable convertible preferred stock		0	37,552
Payments of stock issuance costs		(12,851)	0
Pre-closing stock repurchase		(22,027)	0
Proceeds from issuance of common stock, recapitalization		197,686	0
Proceeds from PIPE		75,000	0
Proceeds from repayment of promissory notes associated with vested and unvested shares		1,193	0
Proceeds from exercise of Class A common stock warrants		808	0
Proceeds from exercise of vested and unvested stock options, net of repurchases and cancelations		254	45
Repayments of principal on term loan		0	(1,515)
Payments for taxes related to net share settlement of equity awards		(4,458)	0
Net cash provided by financing activities		235,605	36,082
Foreign currency effect on cash and cash equivalents		(19)	(12)
Increase in cash, cash equivalents, and restricted cash		79,651	23,855
Cash, cash equivalents, and restricted cash at beginning of period*	[1]	28,350	22,797
Cash, cash equivalents, and restricted cash at end of period*	[1]	108,001	46,652
Supplemental disclosures of cash flow information
Cash paid for taxes		227	197
Cash paid for interest		0	10
Non-cash investing and financing activities
Expiration of Class A common stock redemption right		0	4,500
Exercise of convertible preferred stock warrants		0	3,840
Recapitalization of redeemable convertible preferred stock from pre-closing stock repurchase		125	0
Conversion of redeemable convertible preferred stock to common stock		249,837	0
Assumption of Merger warrants liability		51,814	0
Exercise of Class A common stock warrants		20,872	0
Reclassification of deferred transaction costs		3,929	0
Conversion of Series D preferred stock warrants to Class A common warrants		1,160	0
Change in transaction costs payable		568	0
Vesting of early exercised stock options		106	20
Common stock issued, contingent consideration, and payables for acquisition of business		4,064	0
Equity awards classified as prepaid expenses		$ 2,500	$ 0

[1] As of June 30, 2021, the Company had cash and cash equivalents of $107.1 million and restricted cash of $0.9 million, for total cash, cash equivalents, and restricted cash of $108.0 million. As of December 31, 2020, the Company had cash and cash equivalents of $27.3 million and restricted cash of $1.0 million, for total cash, cash equivalents, and restricted cash of $28.4 million.